| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
During its 20-plus-year history, MVB Bank has grown from a community bank with 35 employees to a forward-thinking, NASDAQ-listed, Russell 2000® company with more than 400 Team Members living in more than 25 different states. Headquartered in Fairmont, West Virginia, MVB Bank and the Banks subsidiaries, the MVB Community Development Corp., Chartwell Compliance, Paladin and Trabian, provide financial services to individuals and corporate clients in the Mid-Atlantic region and beyond. MVB Financial Corp., the holding company of MVB Bank, is publicly traded on The Nasdaq Capital Market under the ticker "MVBF."
Focus on joint success We are one of the international market and technology leaders for innovative laser marking systems. As a global brand and technology center for laser marking solutions, we are part of the Product Quality and Identification segment of the publicly traded Veralto Corporation. FOBA is a leader in camera-based precision systems, machines and workflows for laser marking and engraving. We help our customers to ensure the traceability of their products, to protect their quality and brands, to design products and to respond to trends and regulations at an early stage – especially in our key markets of medical technology and the automotive, aerospace and electronics industries. With decades of laser application expertise, technology leadership in camera-assisted laser marking and consistent customer and service orientation, we can refer to several thousand successfully installed systems worldwide. https://www.fobalaser.com Imprint: https://www.fobalaser.com/legal-notice/ FOBA Laser Marking + Engraving Brand of ALLTEC Angewandte Laserlicht Technologie GmbH
Invisible is the operations innovation company transforming how companies are built and run. Our tech-enabled service harnesses our proprietary process orchestration platform, which seamlessly blends AI and automation with a global team of over 2000 highly-skilled agents. This integration eliminates execution bottlenecks and opens up new efficiency, scale, and growth possibilities for clients, delivering any operations capability better, faster, and cheaper than traditional 20th century services companies.